ResMed Inc.
HealthcareNYSE:RMD · New York Stock Exchange
+$1.37 today
Vol 0.87M · Avg 1.30M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
23.5%
avg 20.6%
ROIC
19.6%
avg 15.1%
ROA
17.1%
avg 12.8%
Analysis
ROE is currently the strongest return metric at 23.5% versus its period average of 20.6%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Michael J. Farrell | Chief Executive Officer & Chairman | $2.97M | — | 54 | $471,214.00 | 0.32% |
Justin Leong | Chief Product Officer | $1.31M | — | 49 | $29,028.00 | 0.02% |
Brett A. Sandercock | Advisor | $971,973.00 | — | 59 | $0.00 | <0.01% |
Aaron Bloomer | Chief Financial Officer | $971,973.00 | — | 40 | $0.00 | <0.01% |
Michael Rider | Chief Legal Officer & Secretary | $889,117.00 | — | 68 | $471,214.00 | 0.32% |
Peter C. Farrell | Founder, Chair Emeritus & Non-Executive Director | $413,215.00 | — | 84 | $471,214.00 | 0.32% |
Vered Keisar | Chief People Officer | — | — | — | — | — |
Jim Ellis | Chief Compliance Officer | — | — | — | — | — |
Sallilyn Schwartz | Chief Investor Relations Officer | — | — | — | — | — |
Yvonne-Katrin Pucknat | Chief Marketing Officer | — | — | 50 | — | — |
Alastair Robertson | Chief Information Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
38
$29.18M
Net Sentiment
$29.18M
Net selling
Most Active
Farrell Michael J.
12 transactions
1–10 of 38
Analysis
Insiders reported 0 buys worth $0.00 and 38 sells worth $29.18M over the last 12 months. That adds up to net selling of $29.18M. Farrell Michael J. was the most active insider with 12 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +13.0% | +13.3% (15yr)2 analysts |
| Revenue | N/A | N/A | +7.1% | +10.7% (15yr)12 analysts |
| Net Income | N/A | N/A | +11.5% | +13.6% (15yr)12 analysts |
| EBIT | N/A | N/A | +11.6% | +13.8% (15yr)12 analysts |
Analysis
Recent growth has been strongest in EPS at +13.0% over three years. Forward estimates point to EBIT at +13.8% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Becton, Dickinson and Company
NYSE:BDX
$52.90B
Cardinal Health, Inc.
NYSE:CAH
$52.49B
Humana Inc.
NYSE:HUM
$45.35B
Haleon plc
NYSE:HLN
$40.37B
Agilent Technologies, Inc.
NYSE:A
$36.58B
Alcon Inc.
NYSE:ALC
$32.54B
IQVIA Holdings Inc.
NYSE:IQV
$29.94B
GE HealthCare Technologies Inc.
NASDAQ:GEHC
$29.56B
Mettler-Toledo International Inc.
NYSE:MTD
$22.89B
Insmed Incorporated
NASDAQ:INSM
$21.23B
Who manages RMD?
ResMed Inc. (RMD) lists 11 active executives. The top listed executive is Michael Rider, Chief Legal Officer & Secretary.
Are RMD insiders buying or selling?
Recent insider activity shows net selling of $39.82M.
Explore More
Continue the stock analysis
Jump to another research area for this company.